Cardiovascular disease is associated with COPD severity and reduced functional status and quality of life

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 11, Issue 5, 2014, Pages 546-551

  Black Shinn, Jennifer L ^a   Kinney, Gregory L ^a   Wise, Anastasia L ^b   Regan, Elizabeth A ^c   Make, Barry ^c   Krantz, Mori J ^d   Barr, R Graham ^e   Murphy, James R ^c   Lynch, David ^c   Silverman, Edwin K ^f   Crapo, James D ^c   Hokanson, John E ^a  

^a Global Health and Health Disparities   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c DEPARTMENT OF MEDICINE   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

co morbidities; pulmonary heart function

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FUNCTIONAL STATUS; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PERIPHERAL VASCULAR DISEASE; QUALITY OF LIFE; SELF REPORT; SMOKING; SPIROMETRY; AGED; CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; COMORBIDITY; EXERCISE TEST; HEALTH STATUS; HOSPITALIZATION; MIDDLE AGED; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; VITAL CAPACITY;

AGED; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; COHORT STUDIES; COMORBIDITY; EXERCISE TEST; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HOSPITALIZATION; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SMOKING; VITAL CAPACITY;

EID: 84907063076     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2014.898029     Document Type: Article

References (29)

1. Sahyoun NR, Lentzner H, Hoyert D, et al. Trends in causes of death among the elderly. Aging Trends 2001; 1-10.
2. Mannino DM, Homa DM, Akinbami LJ, et al. Chronic obstructive pulmonary disease surveillance-United States, 1971-2000. MMWR Surveill Summ 2002; 51:1-16.
3. American Heart Association. Heart disease and stroke statistics-2011 update. Dallas, TX: American Heart Association, 2011.
4. Regan EA, Hokanson JE, Murphy JR, et al. Genetic epidemiology of COPD (COPDGene) study design. COPD 2010; 7:32-43.
5. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26:319-338.
6. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999; 159:179-187.
7. Rodriguez-Roisin R, Anzueto A, Bourbeau J, Calverley P, DeGuia T, Fukuchi Y, Hui D, Jenkins C, Kocabas A, Martinez F, DeOca M, VanWeel C, Vestbo J, Woodhead M, Agusti A, Barnes P, Decramer M, Fabbri L, Jones P, Sin D, Wedzicha J. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2009. http://www.goldcopd.org/Guidelines/guidelines-resources.html.
8. Ferris BG. Epidemiology standardization project (American Th oracic Society). Am Rev Respir Dis 1978; 118:1-120.
9. ATS statement. guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166:111-117.
10. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airfl ow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005-1012.
11. Jones PW. Quality of life measurement for patients with diseases of the airways. Th orax 1991; 46:676-682.
12. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airfl ow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145:1321-1327.
13. Mapel DW, Robinson SB, Dastani HB, et al. The direct medical costs of undiagnosed chronic obstructive pulmonary disease. Value Health 2008; 11:628-636.
14. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases The potential role of systemic infl ammation in chronic obstructive pulmonary disease. Circulation 2003; 107:1514-1519.
15. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of infl ammation in the prediction of coronary heart disease. N Engl J Med 2004; 350:1387-1397.
16. Kosmala W, Derzhko R, Przewlocka-Kosmala M, et al. Plasma levels of TNF-alpha, IL-6, and IL-10 and their relationship with left ventricular diastolic function in patients with stable angina pectoris and preserved left ventricular systolic performance. Coron Artery Dis 2008; 19:375-382.
17. Sakkinen P, Abbott RD, Curb JD, et al. C-reactive protein and myocardial infarction. J Clin Epidemiol 2002; 55:445-451.
18. Bittner V, Weiner DH, Yusuf S, et al. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators. JAMA 1993; 270:1702-1707.
19. Curtis JP, Rathore SS, Wang Y, et al. The association of 6-minute walk performance and outcomes in stable outpatients with heart failure. J Card Fail 2004; 10:9-14.
20. Pinto-Plata VM, Cote C, Cabral H, et al. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J 2004; 23:28-33.
21. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med 1991; 85 Suppl B:25-31.
22. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet 2012; 379:1341-1351.
23. Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Th orac Soc 2005; 2:8-11.
24. Annual smoking-attributable mortality, years of potential life lost, and productivity losses-United States, 1997-2001. MMWR Morb Mortal Wkly Rep 2005; 54:625-628.
25. Smoking-attributable mortality, years of potential life lost, and productivity losses-United States, 2000-2004. MMWR Morb Mortal Wkly Rep 2008; 57:1226-1228.
26. Anthonisen NR, Connett JE, Enright PL, et al. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166:333-339.
27. Stein PK, Nelson P, Rottman JN, Howard D, Ward SM, Kleiger RE, et al. Heart rate variability refl ects severity of COPD in PiZ α1-antitrypsin defi ciency. Chest 1998; 113:327-333.
28. Stewart AG, Waterhouse JC, Howard P. Cardiovascular autonomic nerve function in patients with hypoxaemic chronic obstructive pulmonary disease. Eur Respir J 1991; 4:1207-1214.
29. Wan ES, Hokanson JE, Murphy JR, Regan EA, Make BJ, Lynch DA, Crapo JD, Silverman EK, and the COPDGene Investigators. Clinical and radiographic predictors of GOLD-Unclassifi ed smokers in the COPDGene study. Amer J Respir Criti Care Med 2011; 184:57-63.